Broken Benefits

The episode is packed with concrete, non-obvious insights about healthcare cost structure - particularly the misaligned incentives within the broker-PBM-carrier ecosystem, the rebate trap, and the strategic advantage of reference-based pricing. However, some sections repeat concepts (e.g., fixed vs. controllable costs) and there are moments of filler (sponsor interruptions, throat-clearing). The density is consistently high but not exceptional; most claims are substantiated with examples.

“Rebates are bad. Anytime you're receiving a rebate, that is your first indication that you're overpaying for care, full stop.”

“In reality that MRI actually cost $500. You're now paying $800 for a procedure that costs 500. You're feeling really good about it and you're paying 60% more.”

The core insights - particularly the rebate critique, the carrier pricing inflation scam, and the explicit recommendation to eliminate PBMs entirely - are relatively fresh within the B2B podcast space, though the RBP and transparent PBM frameworks are becoming mainstream in employer benefits discourse. The framing of primary care as 6x ROI is novel and valuable, but some arguments (PBM opacity, network discounts as theater) are now circulating among benefits leaders. Not groundbreaking, but noticeably ahead of conventional wisdom.

“I would even make the point that I'm now questioning, what do you even need a PBM for? When you really get into it and look at the supply chain and follow the money.”

“primary care is the highest ROI investment that you can make in healthcare, without question. And it's the most underutilized.”

Paul Dumas is a senior CHRO (20+ years) who has executed major healthcare transformation at a provider organization and demonstrated real agency - not a consultant or thought-leader-for-hire, but a practitioner who made $1.5M broker fee discovery, negotiated rebate elimination, switched TPAs, and deployed RBP. He has skin in the game, operates at scale ($100M healthcare budget), and can speak to resistance encountered and results achieved. High-caliber operator.

“I've been a chro for well over 20 years. Had the opportunity to work for both private equity backed and publicly traded organizations.”

“In year one we were in hard savings. After doing the RFPs across the ecosystem, we were able to identify 8 and a half million dollars in savings. So we reinvested 50% of that...In year two, the total savings was closer to $24 million.”

The episode contains many concrete details: $1.5M vs. $300K broker fee, 19.5% trend spike, $15M GLP1 budget surprise, 8.5M and 24M in savings (years 1-2), $100M healthcare budget, 98% claims processed cleanly under RBP, .003 (1/3 of 1%) forced provider switches, MRI pricing example ($4K list → $800 paid → $500 actual cost). However, some claims lack numbers: no specific timeline for mental health ROI, vague 70 - 80% cardiometabolic disease cost attribution, no named provider or TPA vendors discussed. Strong but not exhaustive.

“There typically spend the 3 to 400,000 a year for a broker relationship. And we were paying them, um, about $1.5 million.”

“At that time the expense was going up in double digits. So it was really had the focus of our CFO and CEO and then ultimately our leadership team...our trend was 19 and a half percent.”

The host (Lee Lewis) asks thoughtful, substantive follow-up questions and demonstrates genuine curiosity - he probes the rebate paradox, pushes on PBM necessity, and poses the thought experiment on why there's no LBM or IBM. However, the conversation is often more of a guided narrative than a sharp interrogation; Lee frequently echoes Paul's points ("that's totally right") rather than testing claims, and rarely challenges assertions. There's minimal productive disagreement. The pacing is conversational but sometimes meanders without cutting through. Sponsor breaks disrupt momentum.

“I want to pause on that for a second because so many people don't understand this point and look at and agonize over maximizing rebates. What I'm hearing here is, no, that's the wrong, that's the totally the wrong approach.”

“Why don't we have an LBM or an IBM, an imaging benefit manager and a lab benefit manager? The characteristics are very similar.”